Clinical trials: Indigestion
Dyspepsia, Helicobacter Pylori Infection
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H.
- Trial name
- ERADICATE Hp (NCT01980095)
- Testing
- RHB-105
- Where
- 12 sites in United States
- Volunteers
- 119 people
- Sponsor
- RedHill Biopharma Limited
Gastroesophageal Reflux Disease, Dyspepsia
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with…
- Trial name
- NCT01869491
- Testing
- Compound Sodium Alginate Double Action Chewable Tablets
- Where
- 2 sites in China
- Volunteers
- 1,107 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Helicobacter Pylori Infection, Dyspepsia
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H.
- Trial name
- ERADICATE Hp2 (NCT03198507)
- Testing
- RHB-105, Active Comparator
- Where
- 55 sites in United States
- Volunteers
- 455 people
- Sponsor
- RedHill Biopharma Limited
Post-cholecystectomy Gastrointestinal Spasms
Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm
Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg bis in die = twice a day (BID) and changes in quality of life in patients with…
- Trial name
- ODYSSEY (NCT02260154)
- Testing
- Mebeverine
- Where
- 21 sites in Russia
- Volunteers
- 220 people
- Sponsor
- Abbott
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Gastroesophageal Reflux Disease With Dyspepsia Symptoms
Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms
To evaluate the efficacy of 4-week lansoprazole (Takepron) therapy for subjective symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms
- Trial name
- LEGEND (NCT01990339)
- Testing
- Lansoprazole
- Volunteers
- 14,965 people
- Sponsor
- Takeda
Dyspepsia, Irritable Bowel Syndrome
A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G
A randomized, sham-controlled, single-centre pilot investigation designed to compare two parallel groups, gammaCore®-G (active treatment) and a sham, (inactive) treatment in subjects with FGIDs.
- Trial name
- NCT02388269
- Testing
- gammaCore®-G
- Where
- United Kingdom
- Volunteers
- 91 people
- Sponsor
- ElectroCore INC
Functional Dyspepsia
A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)
The purpose of this study is to assess the efficacy and safety of rabeprazole compared to placebo in Japanese subjects with Functional Dyspepsia.
- Trial name
- NCT01089543
- Testing
- Rabeprazole
- Where
- 46 sites in Japan
- Volunteers
- 338 people
- Sponsor
- Eisai Co., Ltd.
Dyspepsia
Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients
Purpose of the study: To obtain additional data on efficacy and safety of Kolofort in the treatment of patients with functional dyspepsia.
- Trial name
- NCT03119766
- Testing
- Kolofort
- Where
- 32 sites in Russia
- Volunteers
- 370 people
- Sponsor
- Materia Medica Holding